Ro, a direct-to-consumer health and wellness company, has partnered with Eli Lilly to provide more affordable access to weight loss medication Zepbound. Through this collaboration, Ro integrates with LillyDirect, Eli Lilly's self-pay pharmacy platform, enabling Ro-affiliated providers to prescribe Zepbound's lower-cost, single-dose vials directly to patients.

This offering aims to enhance accessibility for clinically eligible patients by delivering the medication at self-pay prices directly to their homes. Ro's holistic healthcare approach combines diagnosis, treatment, and ongoing care management into a seamless experience. The goal is to reduce barriers to care, improve treatment adherence, and provide personalized patient journeys.

Zepbound vials are available in 2.5-mg and 5-mg dosages for $399 and $549 per month, respectively. These prices represent a more affordable option for patients without insurance coverage. The launch follows Eli Lilly's introduction of Zepbound at discounted prices, offering significant savings compared to other GLP-1 medications for obesity.

Ro's commitment to innovation includes its earlier launch of the Ro Body weight loss program, which provides GLP-1 access alongside personalized care plans, diagnostic testing, and coaching. The company also introduced an online GLP-1 supply tracker to help patients navigate drug shortages.

Ro’s CEO, Zach Reitano, highlighted the patient-centric approach of this integration, emphasizing its role in streamlining access to FDA-approved obesity treatments directly through the Ro app. Both companies aim to expand access to safe and effective obesity care while addressing affordability and convenience challenges.

Click here to read the original news story.